Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation

doi:10.3748/wjg.v19.i48.9189

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 48

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6379)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

432

HTML

3690

Figures (1-2)

158

Tables (1-1)

200

Sum=4480

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1058

Download

841

Sum=1899

Dec 28, 2013 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (22)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Dec 28, 2013; 19(48): 9189-9197
Published online Dec 28, 2013. doi: 10.3748/wjg.v19.i48.9189

Open in New Tab Full Size Figure Download Figure

Figure 1 Risk of recurrence of hepatitis B virus infection after liver transplantation in relation to the type of post-transplant hepatitis B virus prophylaxis[64]. HBIG: Hepatitis B immunoglobulin; LAM: Lamivudine; ETV: Entecavir; TDF: Tenofovir; LT: Liver transplantation.

Open in New Tab Full Size Figure Download Figure

Figure 2 Proposed algorithm for allocation and management of anti-hepatitis B core positive liver grafts. Such grafts should be first offered to hepatitis B surface antigen positive, then to anti-hepatitis B core (HBc) and/or anti-hepatitis B surface (HBs) positive and lastly to hepatitis B virus naive (both anti-HBc and anti-HBs negative) recipients[79]. LT: Liver transplantation; HBIG: Hepatitis B immunoglobulin; LAM: Lamivudine.

Citation: Cholongitas E, Papatheodoridis GV. Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation. World J Gastroenterol 2013; 19(48): 9189-9197
URL: https://www.wjgnet.com/1007-9327/full/v19/i48/9189.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i48.9189